Pacific Edge Limited Ordinary Shares
PEB.NZXHealth Care
Pacific Edge Limited (NZX: PEB) is a New Zealand publicly listed, cancer diagnostic company specialising in the discovery and commercialisation of diagnostic and prognostic tests for better detection and management of cancer. Its Cxbladder suite of non-invasive, simple to use and accurate diagnostic tests provide actionable results, and better detection and management of urothelial cancer. The company is developing and commercialising its range of Cxbladder bladder cancer tests globally through its wholly owned central laboratories in New Zealand and the USA. The company’s products have been tested and validated in international multi-centre clinical studies.
Market Data
$0.275
+0.1%$341.5M
-7.2x
$-0.038
0.00%
+1.7%
Latest Earnings
Pacific Edge APAC Operations Advance Towards Profit
14 July 2026
Pacific Edge (PEB) reports strong APAC operational momentum in Q1 FY27, with commercial test volumes rising 12.9% to 1,158 tests and APAC cash burn reducing to NZ$0.17M for the quarter, advancing the region towards direct-cost profitability. In the US, commercial tests declined modestly 2.4% to 3,295, reflecting deliberate sales force reduction to 5 FTEs as part of capital preservation ahead of the Novitas Medicare Local Coverage Determination. The company is now pivoting its US strategy toward integrated delivery networks and intermediate-risk microhematuria patients, with a final LCD expected before end of calendar 2026 and commercial payers covering 10.5 million lives already ready to reimburse. Key points: APAC commercial test volumes rose 12.9% quarter-on-quarter to 1,158 tests in Q1 FY27, with APAC cash burn reduced to NZ$0.17M — an improvement of ~15% on Q1 FY26 and ~9% on Q4 FY26; APAC contributed 19% of operating revenue in 2H FY26, up from 8% in FY25, driven by a 25% repricing uplift and a 20% further revenue uplift from Triage Plus mix shift; US sales force efficiency improved sharply to 659 commercial tests per sales FTE in Q1 FY27 from 440 in Q4 FY26, and ordering clinicians rose 7% to 814
Recent Announcements
Pacific Edge APAC Operations Advance Towards Profit
Pacific Edge (PEB) reports strong APAC operational momentum in Q1 FY27, with commercial test volumes rising 12.9% to 1,158 tests and APAC cash burn reducing to NZ$0.17M for the quarter, advancing the region towards direct-cost profitability. In the US, commercial tests declined modestly 2.4% to 3,295, reflecting deliberate sales force reduction to 5 FTEs as part of capital preservation ahead of the Novitas Medicare Local Coverage Determination. The company is now pivoting its US strategy toward integrated delivery networks and intermediate-risk microhematuria patients, with a final LCD expected before end of calendar 2026 and commercial payers covering 10.5 million lives already ready to reimburse. Key points: APAC commercial test volumes rose 12.9% quarter-on-quarter to 1,158 tests in Q1 FY27, with APAC cash burn reduced to NZ$0.17M — an improvement of ~15% on Q1 FY26 and ~9% on Q4 FY26; APAC contributed 19% of operating revenue in 2H FY26, up from 8% in FY25, driven by a 25% repricing uplift and a 20% further revenue uplift from Triage Plus mix shift; US sales force efficiency improved sharply to 659 commercial tests per sales FTE in Q1 FY27 from 440 in Q4 FY26, and ordering clinicians rose 7% to 814
Capital Change Notice - Issue of Options
Pacific Edge Limited (NZX: PEB) issued 111,405 options to acquire ordinary shares on 7 July 2026 as part of its employee long-term incentive plan, with exercise prices ranging from NZ$0.338 to NZ$0.427 per share and vesting in three equal annual tranches. The options represent 0.01% of total ordinary shares on issue and bring total options outstanding to 45,710,105.
Director Nomination Closing Date
Pacific Edge Limited (NZX, ASX: PEB) announces its Annual Shareholder Meeting will be held on 20 August 2026 in Auckland, with the closing date for director nominations set at 21 July 2026 at 4:00pm. Shareholder nominations must be submitted with written consent from the nominated person.
Annual Report 2026
Pacific Edge Limited (PEB) reported FY26 results for the year ended 31 March 2026, with operating revenue falling 47.4% to NZ$11.5M (total revenue $13.6M) as the Medicare non-coverage determination effective April 2025 severely disrupted US test volumes. The net loss after tax widened 19.5% to $35.8M, though the company reduced expenses by 9.5% and cut monthly cash burn by 27.7% in 2H26 versus 1H26. A major post-balance-date catalyst emerged with Novitas publishing a draft Local Coverage Determination (draft LCD DL40378) in May 2026 proposing Medicare coverage for Cxbladder Triage and Triage Plus, with final effective coverage expected by end of calendar year 2026, alongside $36.1M in new equity raised. Key points: Post-balance-date draft Medicare LCD (DL40378) published May 2026 proposes coverage for Cxbladder Triage and Triage Plus — the only urine-based biomarkers proposed for reimbursement — with final effective coverage expected by end of calendar 2026; Novitas confirmed claim-by-claim reimbursement can commence for intermediate-risk microhematuria patients in line with the draft LCD, providing near-term revenue support; Monthly cash burn reduced 27.7% in 2H26 vs 1H26 (to $2.4M/month unaudited) through disciplined cost control including a 9.5% reduction in total expenses vs FY25
D&O Disclosures - Multiple
Multiple Pacific Edge Limited directors and the CEO acquired ordinary shares in June 2026 through a retail offer and placement: Anna Kate Stove increased holdings from 267,100 to 294,552 shares, Sarah Natalie Park from 218,600 to 228,600 shares, Antony George Barclay from 450,000 to 538,235 shares, and CEO Peter Meintjes from 1,291,012 to 2,675,902 shares (plus existing options), with total consideration ranging from $2,000 to $15,000 per director.
SPH Notice - ANZ New Zealand Investments Limited
ANZ New Zealand Investments Limited changed substantial holding from 18.221% to 17.185%.
ASX - 2A - Capital Change
Pacific Edge Limited (PEB) applied for quotation of 69,836,561 ordinary fully paid shares on June 4, 2026, comprising: 62,704,581 shares from a retail offer at NZD 0.17 per share, 470,588 shares issued to professional service providers for capital raising services valued at NZD 80,000, and 6,661,392 shares issued to employees under an incentive scheme in lieu of compensation.
Capital Change Notice - Pacific Edge
Pacific Edge Limited issued 69,836,561 ordinary shares on 4 June 2026 at NZ$0.170 per share, comprising 62.7 million shares via retail offer, 6.7 million shares to employees as performance incentives, and 0.47 million shares for professional services, representing 5.959% of the company's total share class.
PEB Completes Oversubscribed NZ$36.1m Capital Raise
Pacific Edge (NZX/ASX: PEB) completed a NZ$36.1 million capital raising, comprising a NZ$25.4 million placement and a NZ$10.7 million retail offer that was significantly oversubscribed with NZ$46.0 million in applications; 62.7 million new shares will be issued at NZ$0.17 per share, with over 93% of capital coming from existing shareholders.
SPH Notice - Harbour Asset Management Limited
Harbour Asset Management Limited changed substantial holding from 9.957% to 11.144%.
Get real-time alerts for PEB
Receive AI-powered earnings summaries and instant notifications when Pacific Edge Limited Ordinary Shares releases results.
Register Free